Price
No data yet.
Social Signal Score
Revenue
$41.75M-9.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Barr IV
- Sector
- Consumer Cyclical
- Industry
- Leisure
- Employees
- 411
- Beta
- 1.59
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.05
Financials
Revenue
$41.75M-9.7%Net Income
$-4.92M-455.8%EBITDA
$1.64M+22.6%Free Cash Flow
$-3.54MEPS (diluted)
$-0.15-475.0%Shares Outstanding (diluted)
32.35M+2.8%Operating Expenses
$18.74MCash & Debt
$17.33MReturn of Capital
$0.00Revenue by Segment (annual)
$286.77MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $286.77M | $-107.49M | $-3.40 |
| 2021 | $589.53M | $-22.20M | $-0.72 |
| 2020 | $552.56M | $59.85M | $1.99 |
| 2019 | $309.29M | $-92.80M | $-3.13 |
| 2018 | $396.75M | $14.66M | $0.49 |
| 2017 | $406.18M | $26.27M | $0.86 |
| 2016 | $406.04M | $34.18M | $1.10 |
| 2015 | $335.76M | $26.60M | $0.85 |
| 2014 | $274.45M | $18.80M | $0.60 |
| 2013 | $218.80M | $47.95M | $1.54 |
| 2012 | $193.93M | $16.88M | $0.55 |
| 2011 | $180.41M | $1.42M | $0.05 |
| 2010 | $168.45M | $-22.84M | $-0.74 |
| 2009 | $189.26M | $-53.30M | $-1.74 |
Valuation
NLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-25.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Negative
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a
View source ↗ - Newsbusinesswire.com·2d ago·Negative
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired assets from Tennessee-based Nautilus Pharmacy.
View source ↗
Earnings
Typical surprise -7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 8$-0.48 vs $-0.29miss
- Wed, Aug 9$-0.33 vs $-0.50beat
- Tue, May 23$-0.56 vs $-0.52miss
- Thu, Feb 9$-0.35 vs $-0.30miss
- Wed, Nov 9$-0.48 vs $-0.51beat
Estimates and results for NLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NLS officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.